scholarly journals Efficacy and Safety of, and Patient Satisfaction with, Colonoscopic-Administered Fecal Microbiota Transplantation in Relapsing and Refractory Community- and Hospital-Acquired Clostridium difficile Infection

2014 ◽  
Vol 28 (8) ◽  
pp. 434-438 ◽  
Author(s):  
Muhammad Ali Khan ◽  
Aijaz Ahmed Sofi ◽  
Usman Ahmad ◽  
Osama Alaradi ◽  
Abdur Rahman Khan ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Clostridium Difficile ◽  
Fecal Microbiota Transplantation ◽  
Bowel Function ◽  
Fecal Microbiota ◽  
Efficacy And Safety ◽  
Cure Rate ◽  
Symptomatic Infection ◽  
Telephone Surveys ◽  
Hospital Acquired

OBJECTIVE: To report the efficacy and safety of, and patient satisfaction with, colonoscopic fecal microbiota transplantation (FMT) for community- and hospital-acquired Clostridium difficile infection (CDI).METHODS: A retrospective medical records review of patients who underwent FMT between July 1, 2012 and August 31, 2013 was conducted. A total of 22 FMTs were performed on 20 patients via colonoscopy. The patients were divided into ‘community-acquired’ and ‘hospital-acquired’ CDI. Telephone surveys were conducted to determine procedure outcome and patient satisfaction. Primary cure rate was defined as resolution of diarrhea without recurrence within three months of FMT, whereas secondary cure rate described patients who experienced resolution of diarrhea and return of normal bowel function after a second course of FMT.RESULTS: Nine patients met the criteria for community-acquired CDI whereas 11 were categorized as hospital-acquired CDI. A female predominance in the community-acquired group (88.89% [eight of nine]) was found (P=0.048). The primary cure rate was 100% (nine of nine) and 81.8% (nine of 11 patients) in community- and hospital-acquired CDI groups, respectively (P=0.189). Two patients in the hospital-acquired group had to undergo a repeat FMT for persistent symptomatic infection; the secondary cure rate was 100%. During the six-month follow-up, all patients were extremely satisfied with the procedure and no complications or adverse events were reported.CONCLUSION: FMT was a highly successful and very acceptable treatment modality for treating both community- and hospital-acquired CDI.

Fecal Microbiota Transplantation and Emerging Treatments for Clostridium difficile Infection

2013 ◽  
Vol 26 (5) ◽  
pp. 498-505 ◽  
Author(s):  
Krista D. Gens ◽  
Ramy H. Elshaboury ◽  
Jessica S. Holt
Keyword(s):  
Health Care ◽  
Clostridium Difficile ◽  
Health Care Providers ◽  
Clostridium Difficile Infection ◽  
Fecal Microbiota Transplantation ◽  
Treatment Options ◽  
Fecal Microbiota ◽  
Care Providers ◽  
Efficacy And Safety ◽  
Emerging Treatments

Due to the increased incidence and recurrence of Clostridium difficile infection, health care providers are seeking new and alternative treatments to the standard antibiotic therapy. The objective of this article is to present a review on the background, microbiologic efficacy, clinical efficacy, and safety of fecal microbiota transplantation and to provide an overview of emerging treatment options currently under investigation. Emerging treatment options discussed include the use of monoclonal antibodies directed against toxins A and B, C difficile vaccination, and transplantation of nontoxigenic C difficile strains.

Clostridium difficile: Antikörpertherapie und Impfungen

2019 ◽  
Vol 144 (12) ◽  
pp. 842-849 ◽  
Author(s):  
Emil Christian Reisinger ◽  
Meinolf Ebbers ◽  
Micha Löbermann
Keyword(s):  
Clinical Trials ◽  
Clostridium Difficile ◽  
Fecal Microbiota ◽  
Preventive Strategies ◽  
Efficacy And Safety ◽  
Fecal Microbiota Transplant ◽  
Toxin B ◽  
Vaccine Candidates ◽  
Hospital Acquired ◽  
Risk Of Relapse

AbstractHospital-acquired Clostridium difficile infections have become much more frequent in recent years. Besides treatment with antibiotics and fecal microbiota transplant, new preventive strategies are available now. Bezlotoxumab is an antibody against toxin B and may reduce the risk of relapse by roughly 10 %. Several vaccine candidates against toxins A and B and surface-associated antigens were immunogenic and are tested in clinical trials to investigate the efficacy and safety.

Fecal Microbiota Transplantation for Clostridium difficile Infection: A One-Center Experience

2019 ◽  
Vol 37 (6) ◽  
pp. 467-472 ◽  
Author(s):  
Shaina M. Lynch ◽  
Jinjian Mu ◽  
James J. Grady ◽  
Richard G. Stevens ◽  
Thomas J. Devers
Keyword(s):  
Clostridium Difficile ◽  
Fecal Microbiota Transplantation ◽  
Population Sample ◽  
Complete Recovery ◽  
Fecal Microbiota ◽  
Medical Chart Review ◽  
Antibiotic Associated Diarrhea ◽  
Close Relatives ◽  
Hospital Acquired

Background: Clostridium difficile is a gram-positive, anaerobic, and spore-forming bacillus, which is responsible for the majority of antibiotic-associated diarrhea and colitis. Objective: Determine if fecal microbiota transplantation (FMT) is effective in a population sample from Connecticut. Methods: We report the clinical experience of 92 consecutive patients from one gastroenterology practice in central Connecticut treated by colonoscopy with FMT for infection with Clostridium difficile from 2012 to 2017. The analyses are based on clinical follow-up up to 3 months after the FMT procedure and on medical chart review. Results: Overall, complete recovery occurred in 86% of patients. As previously reported in a limited number of previous studies, community-acquired cases were more common than hospital-acquired cases, and community-acquired cases were more likely to be female. Conclusions: Consistent with some previous reports, we found the following: the source of the donor for FMT did not make a difference in recovery: material from nonrelatives was as effective as from close relatives; and the presence of multiple comorbidities did not make a difference in recovery: patients with 2 or more comorbidities did as well as those with one or none.

scholarly journals Clostridium difficile infection in patients after solid organ transplantations

2020 ◽  
Vol 74 ◽  
pp. 198-204
Author(s):  
Sylwia Dudzicz ◽  
Marcin Adamczak ◽  
Andrzej Więcek
Keyword(s):  
Clostridium Difficile ◽  
General Population ◽  
Immunosuppressive Therapy ◽  
Clostridium Difficile Infection ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Solid Organ ◽  
Proper Treatment ◽  
Efficacy And Safety ◽  
Antibiotic Associated Diarrhea

Clostridium difficile is the most common identified pathogen causing nosocomial and antibiotic-associated diarrhea. The incidence of Clostridium difficile infection (CDI) has increased over the last decades. The occurrence of severe and recurrent CDI is also more often recently observed. Patients after solid organs transplantation are more prone to Clostridium difficile infection that the general population. This is associated mainly with immunosuppressive therapy, more frequent hospitalizations and frequent antibiotic therapy. Due to the growing number of CDI, it is important to correctly diagnose this infection and to implement the proper treatment. The main drugs used to treat CDI are vancomycin and fidaxomicin. In the case of CDI recurrence, fecal microbiota transplantation remains to be considered. The rationale use of antibiotics and avoiding proton pump inhibitors may also prevent CDI. Results of recent observational study suggest that one of the probiotics – Lactobacillus plantarum 299v prevents CDI in patients during immunosuppressive therapy. The efficacy and safety of using probiotics in CDI prophylaxis in this group of patients requires, however, further studies.

Sign in / Sign up

Export Citation Format

Share Document